Evogene Ltd. Receives Nasdaq Minimum Bid Price Notification and Faces Delisting Risk

Nasdaq Notification

On 2 April 2026, Evogene Ltd. (NASDAQ: EVGN) received a letter from Nasdaq Stock Market LLC indicating non‑compliance with Nasdaq Rule 5550(a)(2). The company’s closing bid price has remained below $1.00 per share for 30 consecutive business days, violating the minimum bid price requirement for the Nasdaq Capital Market.

The letter provides a 180‑day period—until 28 September 2026—for the company to regain compliance. To achieve this, the closing bid price must reach at least $1.00 for a minimum of ten consecutive business days at any point within this period. If compliance is restored, Nasdaq will issue written confirmation and the matter will be closed.

Potential Delisting

Should Evogene fail to meet the bid‑price requirement before the 180‑day deadline, Nasdaq will issue a delisting notice. The company may then be eligible for an additional 180‑day grace period if it satisfies other listing standards, such as the market value of publicly held shares, while still falling short of the bid‑price rule. To qualify for the extended period, Evogene must submit written notice of its intention to cure the deficiency during the second compliance window.

Market Context

Evogene specializes in computational chemistry and generative design of small molecules for pharmaceutical and agricultural applications. The company operates globally with its headquarters in Rehovot, Israel. As of 31 March 2026, its stock closed at $0.809, well below the $1.00 minimum. The 52‑week low, recorded on 29 March 2026, was $0.72, while the 52‑week high, reached on 9 June 2025, stood at $2.42. The market capitalization is approximately $6.79 million, and the price‑earnings ratio is negative at –0.402, reflecting the company’s current financial performance.

Industry Outlook

The agricultural biotechnology sector is projected to expand from $41.1 billion in 2025 to $111.5 billion by 2036, with a compound annual growth rate of 9.5 % (2026‑2036). Growth drivers include nutritional innovation, gene editing, and biofuel advancements. Evogene’s focus on AI‑driven molecule design positions it within this expanding market, but the company must address its Nasdaq compliance status to maintain investor confidence and access to capital markets.

Conclusion

Evogene Ltd. is under a strict compliance deadline imposed by Nasdaq. The company has 180 days to elevate its closing bid price to $1.00 or more for ten consecutive business days. Failure to comply will result in delisting, potentially limiting future growth and market access. The broader agricultural biotechnology market offers significant growth opportunities, but Evogene’s current stock performance and regulatory status present immediate challenges that the company must resolve to sustain its listing and pursue its technology-driven strategy.